Does Emend Stop Nausea After Surgery?
Emend (fosaprepitant dimeglumine for injection, or aprepitant orally) prevents nausea and vomiting after surgery. It blocks substance P from binding to NK1 receptors in the brain, reducing chemotherapy- or surgery-induced nausea. The FDA approves it for postoperative nausea and vomiting (PONV) prevention in adults and children aged 6 months and older when used with other antiemetics like dexamethasone and ondansetron.[1]
How Is Emend Given for Surgery?
A single IV dose of 150 mg fosaprepitant is infused over 20-30 minutes, about 30 minutes before anesthesia ends. It's often combined with a 5-HT3 antagonist (e.g., ondansetron) and a corticosteroid. Oral aprepitant follows a 125 mg dose pre-surgery, then 80 mg daily for 2 days. Trials show it cuts PONV risk by 20-30% over placebo.[1][2]
How Effective Is It Compared to Other Options?
Emend outperforms standalone ondansetron or placebo in moderate-to-high PONV risk patients. A Phase 3 trial with 2,021 adults found 73% nausea-free at 24 hours versus 62% with ondansetron alone. It matches or beats palonosetron combos but adds NK1 coverage for breakthrough nausea. No complete PONV prevention exists; risk factors like female sex, opioids, or motion sickness raise odds.[2][3]
Who Gets Emend After Surgery?
It's for adults and kids at moderate-high PONV risk (e.g., 20-80% baseline). Guidelines from the Society for Ambulatory Anesthesia recommend it for high-risk cases alongside dexamethasone. Not first-line for low-risk patients due to cost.[3]
What Side Effects or Risks Come Up?
Common: fatigue (10-20%), diarrhea (8%), hiccups (5%). Rare serious issues include anaphylaxis (0.2%) or infusion reactions. Avoid with strong CYP3A4 inhibitors like ketoconazole; it interacts with warfarin or hormonal contraceptives. Safe in pregnancy (Category B), but data limited.[1]
When Does the Patent Expire?
Emend's key U.S. patents expired in 2026, with pediatric exclusivity ending January 2027. Generic fosaprepitant approvals began in 2022, but brand remains available. Check DrugPatentWatch.com for litigation updates.[4]
[1]: FDA Label for Emend (aprepitant/fosaprepitant), 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021549s038lbl.pdf
[2]: Gan TJ et al., NEJM 2007;356:2442-2461. https://www.nejm.org/doi/full/10.1056/NEJMoa060949
[3]: Apfel CC et al., Anesthesiology 2012;116:1176-1187. https://pubs.asahq.org/anesthesiology/article/116/6/1176/13977
[4]: DrugPatentWatch.com, Emend patents. https://www.drugpatentwatch.com/p/tradename/EMEND